CLBTW Cellebrite Digital Intelligence Ltd

Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2024.

“Cellebrite delivered a solid fourth-quarter performance to cap an excellent 2024 in which we exceeded our original revenue and adjusted EBITDA targets and delivered at the higher end of our ARR expectations,” stated Thomas E. Hogan, Cellebrite’s interim chief executive officer. “We enjoyed continued success in expanding our share-of-wallet across our global installed base and converting that top-line growth into meaningful year-over improvement in our profitability and free cash flow. As a result, we produced a Rule of 50 performance in 2024 with 25% ARR growth and 25% adjusted EBITDA margins. With multiple macro tailwinds that we believe show no signs of dissipating, we move into 2025 with plans to advance our market and technology leadership, sustain our top-line expansion and continue generating attractive profit margins and robust free cash flow.”

Fourth-Quarter 2024 Financial Highlights

• Revenue of $109.0 million, up 17% year-over-year
• Subscription revenue was $95.1 million, up 21% year-over-year

• Annual Recurring Revenue (ARR) of $395.9 million, up 25% year-over-year
• Recurring revenue dollar-based net retention rate of 124%
• GAAP gross profit and gross margin of $91.4 million and 83.8%, respectively; Non-GAAP gross profit and gross profit margin of $92.0 million and 84.4%, respectively
• GAAP net income of $19.3 million; Non-GAAP net income of $26.1 million
• GAAP diluted earnings per share of $0.08; Non-GAAP diluted earnings per share of $0.10
• Adjusted EBITDA and Adjusted EBITDA margin of $28.8 million and 26.4%, respectively

Full-Year 2024 Financial Highlights

• Revenue of $401.2 million, up 23% year-over-year
• Subscription revenue was $353.0 million, a 26% year-over-year increase
• GAAP gross profit and gross margin of $338.6 million and 84.4%, respectively; Non-GAAP gross profit and gross profit margin of $340.8 million and 85.0%, respectively
• GAAP net loss of $283.0 million; Non-GAAP net income of $97.8 million
• GAAP diluted loss per share of $1.35; Non-GAAP diluted earnings per share of $0.42
• Adjusted EBITDA and adjusted EBITDA margin of $99.4 million and 24.8%, respectively

Fourth-Quarter 2024 and Recent Business & Operational Highlights

Board Governance

• On January 6, 2025, Cellebrite announced a series of Board updates to support the Company’s continued growth into 2025 and beyond:
  • Thomas E. Hogan, previously Cellebrite’s executive chairman, was appointed interim chief executive officer and will remain on the Company’s Board of Directors.
  • Adam H. Clammer, Managing Partner of True Wind Capital Management and Cellebrite’s current lead independent director, succeeded Hogan as board chairman. It is expected that Hogan will revert to board chairman upon the eventual appointment of a new CEO.
  • Michael D. Capellas, a distinguished executive with extensive leadership experience across a range of CIO, CEO and board chairman and director positions at a number of the world’s most successful software and technology companies, has been appointed to Cellebrite’s Board of Directors as a Class II director and will serve as the Board’s lead independent director.

Go-to-Market

• On February 11, 2025, Cellebrite published its sixth annual 2025 Industry Trends Survey, highlighting how public safety professionals use and apply powerful digital investigative solutions to uncover digital evidence in criminal investigations and revealing widespread appetite for artificial intelligence and cloud solutions.

Innovation

• On February 12, 2025, Cellebrite announced that its Cellebrite Government Cloud platform has achieved FedRAMP High Ready designation by the Federal Risk and Authorization Management Program (FedRAMP). This milestone, which marks the initial stage in the compliance process, reinforces Cellebrite’s commitment to equipping and empowering its U.S. federal customers with industry-leading cloud security when utilizing the Company’s Software-as-a-Service-based digital investigative solutions.
• On February 6, 2025, Cellebrite announced the general availability of Generative Artificial Intelligence (GenAI) capabilities within Guardian, Cellebrite’s SaaS-based evidence management solution.
• On November 20, 2024, as part of an exclusive technology and go-to-market partnership with Relativity, Cellebrite announced that it had integrated its mobile collection solutions, Endpoint Inspector and Endpoint Mobile Now, into the RelativityOne platform.

Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial-information/quarterly-results.

Financial Outlook

“Cellebrite’s 2024 financial results reflect a balanced mix of top-line growth and strong profitability,” stated Dana Gerner, Cellebrite’s Chief Financial Officer. “Redeeming our warrants and hitting various stock price triggers in 2024 enabled us to optimize our capital structure, support healthy trading liquidity and simplify our 2025 financial reporting. As we look ahead, our outlook for 2025 is aligned with our long-term objective of consistently delivering a Rule of X performance between 45 and 50.”

The Company’s first-quarter and full-year expectations for 2025 are as follows:

		First-Quarter 2025 Expectations(as of 2/13/25)		Full-Year 2025 Expectations(as of 2/13/25)
ARR		$406 million - $411 million		$480 million - $495 million
Annual growth		22% - 24%		21% - 25%
Revenue		$107 million - $112 million		$480 million - $490 million
Annual growth		19% - 25%		20% - 22%
Adjusted EBITDA		$22 million - $24 million		$113 million - $123 million
Adjusted EBITDA margin		~21%		24% - 25%

Conference Call Information

Cellebrite will host a live conference call and webcast later this morning to review the Company’s financial results for the fourth quarter of 2024 and discuss its outlook for 2025. Pertinent details include:

Date:		Thursday, February 13, 2025
Time:		8:30 a.m. ET
Call-In Number:		203-518-9783 / 800-267-6316
Conference ID:		CLBTQ424
Event URL:		https://investors.cellebrite.com/events/event-details/cellebrite-q4-2024-fy-2024-financial-results-investor-call-webcast
Webcast URL:		https://edge.media-server.com/mmc/p/2oayuote

In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results.

Non-GAAP Financial Information and Key Performance Indicators

This press release includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income, non-GAAP EPS and Adjusted EBITDA is helpful to investors. These measures, which the Company refers to as its non-GAAP financial measures, are not prepared in accordance with GAAP.

The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period, and offer investors and management greater visibility into the underlying performance of its business. Mainly:

• Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses;
• Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition, and acquisition-related expenses are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
• To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income;
• Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to the Company’s underlying performance and make period-to-period comparisons more challenging; and
• Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company’s current operations and affect financial income.

Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangible asset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.

A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com.

In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.

This press release also includes key performance indicators, including annual recurring revenue and dollar-based retention rate.

Annual recurring revenue (“ARR”) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue, deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenues, which can be impacted by contract start and end dates and renewal rates.

Dollar-based net retention rate (“NRR”) is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Caution Regarding Forward Looking Statements

This document includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, estimated financial information for the first quarter of 2025 and for fiscal year 2025 and certain statements such as, multiple macro tailwinds that the Company believes show no signs of dissipating; the Company moves into 2025 with plans to advance its market and technology leadership, sustain its top-line expansion and continue generating attractive profit margins and robust free cash flow; and the Company’s outlook for 2025 being aligned with its long-term objective of consistently delivering a Rule of X performance between 45 and 50. Such forward-looking statements including those with respect to 2025 revenue and annual recurring revenue, profitability and earnings as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; Cellebrite’s dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite’s dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 21, 2024 and as amended on April 12, 2024, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital intelligence and accelerating justice in communities around the world. Cellebrite’s AI-powered Case-to-Closure (C2C) platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies and businesses rely on the Company’s cloud-ready digital forensic and investigative solutions to close cases faster and safeguard communities. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com and find us on social media @Cellebrite.

Contacts:

Investors RelationsAndrew KramerVice President, Investor Relationsinvestors@cellebrite.com+1 973.206.7760

Media Victor CooperSr. Director of Corporate Communications + Content OperationsVictor.cooper@cellebrite.com+1 404.804.5910

Cellebrite DI Ltd. Fourth-Quarter 2024 Results Summary (U.S Dollars in thousands)
	For the three months ended						For the year ended
	December 31,						December 31,
	2024			2023			2024			2023
Revenue	109,049			93,013			401,203			325,110
Gross profit	91,425			78,097			338,610			271,879
Gross margin	83.8	%		84.0	%		84.4	%		83.6	%
Operating income	15,727			14,999			56,906			33,237
Operating margin	14.4	%		16.1	%		14.2	%		10.2	%
Net income (loss)	19,269			(14,647	)		(283,007	)		(81,100	)
Cash flow from operating activities	65,967			43,828			132,171			102,058
Non-GAAP Financial Data:
Operating income	26,928			20,982			92,119			55,282
Operating margin	24.7	%		22.6	%		23.0	%		17.0	%
Net income	26,123			21,999			97,761			60,926
Adjusted EBITDA	28,793			22,726			99,377			61,946
Adjusted EBITDA margin	26.4	%		24.4	%		24.8	%		19.1	%

Cellebrite DI Ltd. Condensed Consolidated Balance Sheets (U.S. Dollars in thousands)
		December 31,				December 31,
		2024				2023
Assets
Current assets
Cash and cash equivalents		$	191,659			$	189,517
Short-term deposits			153,746				74,713
Marketable securities			101,818				38,693
Trade receivables (net of allowance for credit losses of $594 and $1,583 as of December 31, 2024 and December 31, 2023, respectively)			82,358				77,269
Prepaid expenses and other current assets			23,246				26,400
Contract acquisition costs			5,827				5,550
Inventories			8,939				9,940
Total current assets			567,593				422,082
Non-current assets
Other non-current assets			7,682				7,341
Marketable securities			36,601				28,859
Deferred tax assets, net			11,072				7,024
Property and equipment, net			16,995				15,896
Intangible assets, net			11,306				10,594
Operating lease right-of-use assets, net			10,604				14,260
Goodwill			28,714				26,829
Total non-current assets			122,974				110,803
Total assets		$	690,567			$	532,885
Liabilities and shareholders’ equity
Current Liabilities
Trade payables		$	11,077			$	8,282
Other accounts payable and accrued expenses			63,330				44,845
Deferred revenues			216,970				195,725
Operating lease liabilities			4,125				4,972
Total current liabilities			295,502				253,824
Long-term liabilities
Other long-term liabilities			6,954				5,515
Deferred revenues			45,247				47,098
Restricted Sponsor Shares liability			—				47,247
Price Adjustment Shares liability			—				81,715
Derivative warrant liabilities			—				54,117
Operating lease liabilities			6,844				9,157
Total long-term liabilities			59,045				244,849
Total liabilities			354,547				498,673
Shareholders’ equity
Share capital			*	)			*	)
Additional paid-in capital			498,883				(84,896	)
Treasury share, NIS 0.00001 par value; 41,776 ordinary shares			(85	)			(85	)
Accumulated other comprehensive income			2,086				1,050
(Accumulated deficit) retained earnings			(164,864	)			118,143
Total shareholders’ equity			336,020				34,212
Total liabilities and shareholders’ equity		$	690,567			$	532,885
*) Less than 1 USD

Cellebrite DI Ltd. Condensed Consolidated Statements of Income (U.S Dollars in thousands, except share and per share data)
		For the three months ended								For the year ended
		December 31,								December 31,
		2024				2023				2024				2023
Revenue:
Subscription services		$	73,848			$	57,722			$	271,028			$	209,751
Term-license			21,220				20,924				82,007				70,663
Total subscription			95,068				78,646				353,035				280,414
Other non-recurring			6,293				4,486				17,285				13,561
Professional services			7,688				9,881				30,883				31,135
Total revenue			109,049				93,013				401,203				325,110
Cost of revenue:
Subscription services			7,156				5,179				26,004				19,219
Term-license			—				—				—				6
Total subscription			7,156				5,179				26,004				19,225
Other non-recurring			4,865				4,344				16,200				13,766
Professional services			5,603				5,393				20,389				20,240
Total cost of revenue			17,624				14,916				62,593				53,231
Gross profit		$	91,425			$	78,097			$	338,610			$	271,879
Operating expenses:
Research and development			25,599				21,751				98,415				84,386
Sales and marketing			35,524				29,594				132,389				110,813
General and administrative			14,575				11,753				50,900				43,443
Total operating expenses		$	75,698			$	63,098			$	281,704			$	238,642
Operating income		$	15,727			$	14,999			$	56,906			$	33,237
Financial income (expense), net			4,170				(27,344	)			(332,890	)			(108,800	)
Income (loss) before tax			19,897				(12,345	)			(275,984	)			(75,563	)
Tax expense			628				2,302				7,023				5,537
Net income (loss)		$	19,269			$	(14,647	)		$	(283,007	)		$	(81,100	)
Earnings (losses) per share
Basic		$	0.08			$	(0.08	)		$	(1.35	)		$	(0.43	)
Diluted		$	0.08			$	(0.08	)		$	(1.35	)		$	(0.43	)
Weighted average shares outstanding
Basic			233,248,045				194,440,674				209,471,827				190,154,549
Diluted			247,353,640				194,440,674				209,471,827				190,154,549
Other comprehensive income:
Unrealized income (loss) on hedging transactions			261				1,311				(487	)			1,252
Unrealized (loss) income on marketable securities			(411	)			293				113				506
Currency translation adjustments			1,820				(946	)			1,410				(1,039	)
Total other comprehensive income, net of tax			1,670				658				1,036				719
Total other comprehensive income (loss)		$	20,939			$	(13,989	)		$	(281,971	)		$	(80,381	)

Cellebrite DI Ltd. Condensed Consolidated Statements of Cash Flow (U.S Dollars in thousands, except share and per share data)
				For the three months ended												For the year ended
				December 31,												December 31,
				2024						2023						2024						2023
Cash flow from operating activities:
Net income (loss)				$	19,269					$	(14,647		)			$	(283,007		)			$	(81,100		)
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based compensation and RSU's					9,269						5,060						30,575						18,998
Amortization of premium, discount and accrued interest on marketable securities					(866		)				(308		)				(2,904		)				(1,106		)
Depreciation and amortization					2,729						2,615						10,607						10,011
Interest income from short-term deposits					(2,836		)				(3,495		)				(10,736		)				(7,737		)
Deferred tax assets, net					(1,813		)				2,290						(4,015		)				5,125
Remeasurement of warrant liability					—						9,785						110,664						34,102
Remeasurement of Restricted Sponsor Shares					—						6,975						65,889						29,715
Remeasurement of Price Adjustment Shares liabilities					—						14,155						173,051						55,531
Decrease (increase) in trade receivables					10,263						(7,067		)				(5,829		)				2,271
Increase in deferred revenue					17,255						22,247						22,317						46,114
(Increase) decrease in other non-current assets					(47		)				231						(341		)				(5,610		)
(Increase) decrease in prepaid expenses and other current assets					(2,885		)				(2,175		)				3,201						(9,211		)
Changes in operating lease assets					1,450						224						5,335						4,362
Changes in operating lease liability					(1,278		)				330						(4,839		)				(4,196		)
Decrease in inventories					746						1,281						982						243
Increase in trade payables					3,917						321						2,755						3,691
Increase in other accounts payable and accrued expenses					11,722						5,571						17,586						734
(Decrease) increase in other long-term liabilities					(928		)				435						880						121
Net cash provided by operating activities					65,967						43,828						132,171						102,058
Cash flows from investing activities:
Purchases of property and equipment					(3,178		)				(2,260		)				(8,566		)				(5,231		)
Cash paid in conjunction with acquisitions, net of acquired cash					—						—						(2,748		)				—
Purchase of Intangible assets					(1,139		)				(2,687		)				(2,043		)				(2,687		)
Investment in marketable securities					(15,079		)				(13,312		)				(127,789		)				(55,317		)
Proceeds from maturity of marketable securities					10,985						12,279						59,971						56,336
Investment in short-term deposits					(39,000		)				(25,000		)				(207,000		)				(89,000		)
Redemption of short-term deposits					31,462						34,141						138,702						73,359
Net cash (used in) provided by investing activities					(15,949		)				3,161						(149,473		)				(22,540		)
Cash flows from financing activities:
Exercise of options to shares					5,756						3,827						17,265						19,142
Proceeds from Employee Share Purchase Plan					974						703						3,344						2,623
Exercise of Warrants					—						—						53						—
Redemption of Warrants					—						—						(11		)				—
Net cash provided by financing activities					6,730						4,530						20,651						21,765
Net increase in cash and cash equivalents					56,748						51,519						3,349						101,283
Net effect of Currency Translation on cash and cash equivalents					(1,438		)				932						(1,207		)				589
Cash and cash equivalents at beginning of period					136,349						137,066						189,517						87,645
Cash and cash equivalents at end of period				$	191,659					$	189,517					$	191,659					$	189,517
Supplemental cash flow information:
Income taxes paid				$	3,801					$	847					$	7,706					$	10,047
Non-cash activities
Operating lease liabilities arising from obtaining right of use assets				$	53					$	3,105					$	1,884					$	4,363
Reclassification of derivative warrants from liability to equity				$	—					$	—					$	164,770					$	—
Reclassification of Restricted Sponsor Shares from liability to equity				$	—					$	—					$	113,136					$	—
Reclassification of Price Adjustment Shares from liability to equity				$	—					$	—					$	254,766					$	—

Cellebrite DI Ltd. Reconciliation of GAAP to Non-GAAP Financial Information (U.S Dollars in thousands, except share and per share data)
	For the three months ended								For the year ended
	December 31,								December 31,
	2024				2023				2024				2023
	(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Cost of revenue	$	17,624			$	14,916			$	62,593			$	53,231
Less:
Share-based compensation		575				498				2,227				1,733
Acquisition-related costs		—				13				2				52
Non-GAAP cost of revenue	$	17,049			$	14,405			$	60,364			$	51,446
	For the three months ended								For the year ended
	December 31,								December 31,
	2024				2023				2024				2023
	(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Gross profit	$	91,425			$	78,097			$	338,610			$	271,879
Share-based compensation		575				498				2,227				1,733
Acquisition-related costs		—				13				2				52
Non-GAAP gross profit	$	92,000			$	78,608			$	340,839			$	273,664
	For the three months ended								For the year ended
	December 31,								December 31,
	2024				2023				2024				2023
	(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Operating expenses	$	75,698			$	63,098			$	281,704			$	238,642
Less:
Issuance expenses		—				—				—				(345	)
Share-based compensation		8,694				4,562				28,348				17,265
Amortization of intangible assets		864				871				3,349				3,347
Acquisition-related costs		—				39				219				(7	)
One-time expense		1,068				—				1,068				—
Non-GAAP operating expenses	$	65,072			$	57,626			$	248,720			$	218,382
	For the three months ended								For the year ended
	December 31,								December 31,
	2024				2023				2024				2023
	(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Operating income	$	15,727			$	14,999			$	56,906			$	33,237
Issuance expenses		—				—				—				(345	)
Share-based compensation		9,269				5,060				30,575				18,998
Amortization of intangible assets		864				871				3,349				3,347
Acquisition-related costs		—				52				221				45
One-time expense		1,068				—				1,068				—
Non-GAAP operating income	$	26,928			$	20,982			$	92,119			$	55,282
	For the three months ended								For the year ended
	December 31,								December 31,
	2024				2023				2024				2023
	(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Net income (loss)	$	19,269			$	(14,647	)		$	(283,007	)		$	(81,100	)
Issuance expenses		—				—				—				(345	)
Share-based compensation		9,269				5,060				30,575				18,998
Amortization of intangible assets		864				871				3,349				3,347
Acquisition-related costs		—				52				221				45
Tax (income) expense		(4,347	)			(252	)			(4,049	)			633
Finance expense from financial derivatives		—				30,915				349,604				119,348
One-time expense		1,068				—				1,068				—
Non-GAAP net income	$	26,123			$	21,999			$	97,761			$	60,926
Non-GAAP Earnings per share:
Basic	$	0.11			$	0.12			$	0.45			$	0.31
Diluted	$	0.10			$	0.11			$	0.42			$	0.28
Weighted average shares outstanding:
Basic		233,248,045				194,440,674				209,471,827				190,154,549
Diluted		250,539,405				207,110,826				227,258,731				206,194,081
	For the three months ended								For the year ended
	December 31,								December 31,
	2024				2023				2024				2023
	(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Net income (loss)	$	19,269			$	(14,647	)		$	(283,007	)		$	(81,100	)
Financial (income) expense, net		(4,170	)			27,344				332,890				108,800
Tax expense		628				2,302				7,023				5,537
Issuance expenses		—				—				—				(345	)
Share-based compensation		9,269				5,060				30,575				18,998
Amortization of intangible assets		864				871				3,349				3,347
Acquisition-related costs		—				52				221				45
Depreciation expenses		1,865				1,744				7,258				6,664
One-time expense		1,068				—				1,068				—
Adjusted EBITDA	$	28,793			$	22,726			$	99,377			$	61,946